Amylyx looks to cover financial gap left by Relyvrio with avexitide deal, says GlobalData GlobalData Jul 2, 2024 The acquisition is a strategic action by Amylyx following the failure of its lead amyotrophic lateral sclerosis (ALS) therapy,…
Amylyx’s efforts to explore other indications for Relyvrio seems to be bearing fruit: GlobalData EP News Bureau Jun 3, 2024 Amylyx explores new indications for Relyvrio after ALS trail setback, with early success in Wolfram syndrome and other…
US FDA approves Amylyx’s ALS drug Reuters Sep 30, 2022 Amylyx's drug is a combination of generic compounds sodium phenylbutyrate and taurursodiol that work together to prevent nerve…
